The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDMTR.L Regulatory News (DMTR)

  • There is currently no data for DMTR

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

DeepMatter Appoints Industry Advisors

16 Dec 2019 07:00

RNS Number : 8960W
DeepMatter Group PLC
16 December 2019
 

DeepMatter Group plc

("DeepMatter", the "Company" or "the Group")

 

DeepMatter Appoints Industry Advisors

DeepMatter strengthens its depth of knowledge and industry links in Research & Medicinal Chemistry, Process Chemistry and Automation

 

16 December 2019 - DeepMatter (AIM: DMTR), the AIM-quoted company focusing on digitising chemistry, is delighted to welcome three leading sector figures as industry advisors on its commercial roll-out of DigitalGlassware™. The advisors bring in-depth knowledge in research & medicinal chemistry, process chemistry and industrially focused closed-loop robotics and automation, all target industries for DigitalGlassware, the Company's innovative cloud-based digital chemistry platform that brings recordability, reproducibility and shareability to the lab.

 

The advisors will contribute to the ongoing development of the DigitalGlassware™ strategic roadmap and are as follows:

 

·; Dr Richard Bourne - a leading academic in Process Chemistry. Richard is Associate Professor at the University of Leeds based at the Institute of Process Research and Development, working on rapid process development and continuous flow chemistry. In November 2019, he was announced as a new Royal Academy of Engineering Senior Research Fellow in Digital Manufacturing and Discovery of Pharmaceuticals.

·; Dr John Harris - a pharmaceutical industry consultant with a wealth of research chemistry knowledge and expertise. John was previously Head of the Wellcome Foundation's UK cardiovascular therapeutic area and founder of BioFocus, a highly successful early-stage CRO, now part of the Charles River organisation.

·; Dr David M Parry - an experienced synthetic chemist, with a track record of delivering complex projects within the pharma and biotech sectors. David built and ran a business focused on automated medicinal chemistry, where compounds would be synthesised, then tested in a primary assay on the same platforms, with the results fed back into the software to inform the next round of automated synthesis.

 

Mark Warne, Chief Executive Officer of DeepMatter, commented:

"We believe DigitalGlassware™ has the opportunity to sit at the heart of the digitisation of chemistry, enabling chemists to produce better molecules, faster and ultimately cheaper. We are delighted to welcome Richard, John and David to the DigitalGlassware™ team, each bringing valuable insight from their three areas of specialism. Their expertise will help ensure the platform meets and integrates the needs of these key disciplines, assisting us in the commercial roll-out of our innovative cloud-based digital chemistry platform."

For more information, please contact:

DeepMatter Group plc

T: 0141 548 8156

Mark Warne, Chief Executive Officer

 

 

 

 

Shore Capital (Nominated Adviser and Broker)

 

T: 020 7408 4050

Tom Griffiths

David Coaten

 

 

 

Alma PR

Caroline Forde

Jessica Joynson

Kieran Breheny

 

T: 020 3405 0205

deepmatter@almapr.co.uk

 

About DeepMatter Group plc

 

DeepMatter's long term strategy is to integrate chemistry with technology, thereby enabling a greater use of artificial intelligence and reaching a point where chemicals can be autonomously synthesised through robotics. In the near term this involves the provision of an integrated software, hardware and artificial intelligence enabled platform, DigitalGlassware™, to scientists across research and process development sectors.

 

The DigitalGlassware™ platform allows chemistry experiments to be accurately and systematically recorded, coded and entered into a shared data cloud. The platform is designed to enable chemists to work together effectively; sharing the details of their experiments from anywhere and in real-time, so that work is not needlessly duplicated, time and money wasted, and ultimately so new discoveries may be made faster.

 

Visit: www.deepmatter.io and follow @deepmattergroup

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAMMMMZNFZGLZM
Date   Source Headline
22nd Mar 201910:39 amRNSHolding(s) in Company
20th Mar 20197:00 amRNSDirectors' Shareholdings
19th Mar 20194:52 pmRNSReplacement - Total Voting Rights and Notice of...
19th Mar 20193:35 pmRNSHolding(s) in Company
19th Mar 20193:32 pmRNSHolding(s) in Company
15th Mar 20198:10 amRNSTotal Voting Rights and Notice of Results
12th Mar 20197:00 amRNSGrant of Options
11th Mar 201912:58 pmRNSResult of Meeting & Directorate Change
7th Mar 20199:00 amRNSIssue of Equity
25th Feb 20197:00 amRNSAcquisition, Placing & Waiver of Rule 9
14th Feb 20193:58 pmRNSHolding(s) in Company
6th Feb 20194:42 pmRNSHolding(s) in Company
6th Feb 20194:41 pmRNSHolding(s) in Company
17th Jan 20197:00 amRNSDisposal of SICM business
20th Dec 20187:00 amRNSUpdate, Conditional Acquisition & Proposed Placing
30th Nov 20187:00 amRNSPublication of Paper in leading Journal
6th Sep 20183:06 pmRNSExercise of Options and Issue of Equity
6th Sep 20187:00 amRNSInterim Results
15th Aug 20187:00 amRNSFurther Pioneer Agreements and Notice of Results
19th Jul 20187:00 amRNSPublication of Scientific Paper
11th Jun 20187:00 amRNSDirectorate Changes
11th Jun 20187:00 amRNSIssue of Equity
16th May 201811:45 amRNSResult of AGM, name change and new website
24th Apr 20187:00 amRNSDirector Dealing
19th Apr 20187:00 amRNSSecond Pioneer Agreement Signed
12th Apr 20187:00 amRNSFirst Pioneer Agreement Signed
5th Apr 20183:28 pmRNSDirector Dealing
28th Mar 20187:00 amRNSFinal results for the year ended 31 December 2017
6th Feb 20187:00 amRNSMoUs signed with pioneers
19th Jan 20189:00 amRNSPublication of Scientific Paper
17th Jan 20187:00 amRNSPublication of Scientific Paper
6th Dec 20177:00 amRNSDirector Dealing
4th Dec 20177:00 amRNSNew Share Option Scheme and Grant to PDMR
1st Dec 20171:01 pmRNSDirectors' Dealing
28th Nov 20179:47 amRNSDirector Dealing
22nd Nov 20175:50 pmRNSHolding(s) in Company
20th Nov 201711:02 amRNSHolding(s) in Company
8th Nov 20178:11 amRNSCompletion of Acquisition, Appointment of Director
3rd Nov 20177:00 amRNSAcquisition of OpenIOLabs Limited
4th Oct 20177:00 amRNSChange of Adviser
12th Sep 20177:00 amRNSHalf-year Report
19th May 201711:34 amRNSResult of AGM
26th Apr 20177:00 amRNSDirectorate Changes
28th Mar 20177:00 amRNSFinal Results
16th Feb 20177:00 amRNSDigital Chemistry to be performed in space
31st Jan 20178:03 amRNSAdvisory Committee
31st Jan 20177:00 amRNSPresentation at Healthcare Conference
9th Jan 20177:00 amRNSDigitalGlasswareT
15th Sep 20167:00 amRNSHalf-year Report
12th May 201611:45 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.